BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Frexalimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Frexalimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06500702-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:Frexalimab: Phase 2 readout est. (NCT06500702)
DESCRIPTION:Frexalimab\, phase 2.\nStudy: A Study to Evaluate the Efficacy 
 and Safety of Frexalimab\, Brivekimig\, or Rilzabrutinib in Participants A
 ged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Mini
 mal Change Disease\nEstimated primary completion: 23 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06500702
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06111586-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Frexalimab: Phase 2 readout est. (NCT06111586)
DESCRIPTION:Frexalimab\, phase 2.\nStudy: Frexalimab in Preservation of End
 ogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on
  Top of Insulin Therapy (FABULINUS)\nEstimated primary completion: 28 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT061115
 86
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141473-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141473)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms o
 f Multiple Sclerosis\nEstimated primary completion: 6 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06141473
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325292-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07325292)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Non-inferior
 ity Study of Frexalimab Subcutaneous Administration Compared to Intravenou
 s Administration in Adult Participants With Multiple Sclerosis\nEstimated 
 primary completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/frexalimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07325292
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141486-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141486)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Second
 ary Progressive Multiple Sclerosis\nEstimated primary completion: 24 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614148
 6
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412470-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Frexalimab: Phase 2/3 readout est. (NCT07412470)
DESCRIPTION:Frexalimab\, phase 2/3.\nStudy: A Study to Investigate the Effi
 cacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidne
 y Transplantation\nEstimated primary completion: 15 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07412470
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930624-7194@assetmemo.bio
DTSTAMP:20261121T005614Z
DTSTART;VALUE=DATE:20310516
DTEND;VALUE=DATE:20310517
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07930624)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: A Study to I
 nvestigate Long-term Safety and Tolerability of Frexalimab in Participants
  With Multiple Sclerosis\nEstimated primary completion: 16 May 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07930624
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
